The firm will use the funding to advance its enzymatic DNA synthesis technology, which has applications in life sciences, information storage, synthetic biology, and electronics.
The Seattle startup is looking to partner with pharmaceutical companies and offer its yeast fusion sequencing technology as a contracted research service.
The company said the money from the transactions will help it boost adoption of its ConfirmMDx and SelectMDx prostate cancer tests with urologists and payors.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.
Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.
US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.
